Sandu Pharmaceuticals Limited is a pharmaceutical company engaged in the manufacturing and marketing of Ayurvedic medicines and healthcare products. The company produces a range of traditional Ayurvedic formulations, including syrups, tablets, powders, oils, and proprietary products. Its offerings cater to various therapeutic categories such as digestive health, respiratory care, and general wellness. Sandu Pharmaceuticals Limited distributes its products through retail, institutional, and export channels. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.

Sandu Pharmaceuticals

Sandu Pharmaceuticals (524703) Q3 25/26 Summary | Quartr

Google Play

App Store

App links

Article Categories

Prefooter USP - CTA App

Dig deeper into the Visa Inc fundamentals on Quartr.

Features CTA

Product

Use cases

Discover

Resources

Company

email

Features

Platforms

Featured article

Pricing

Contact sales

Simple CTA

events-root

Sandu Pharmaceuticals Limited

Q1 FY27 revenue reached ₹1,638.88 lakhs with net profit at ₹22.82 lakhs and EPS at ₹0.37.

Q1 26/27

FY26 saw higher revenue, profit, and cash, with a Rs. 1 dividend and no large borrowings.

Q4 25/26

Q2 FY26 saw higher revenue, improved profit, and robust cash flow in Ayurvedic medicines.

Q2 25/26

Q1 FY26 saw higher revenue and profit, with AGM and dividend record date set for September.

Q1 25/26

Revenue and profit grew modestly; subsidiary wound up; cash reserves increased.

Q2 24/25

Q1 FY25 saw revenue rise to ₹1,704.54 lakhs and a recommended dividend of ₹0.80 per share.

Q1 24/25

Stable financial performance with steady revenue, profit, and no new borrowings or equity changes.

Q4 23/24

FY25 saw steady profit growth, a dividend proposal, and a shift to standalone reporting.

Q4 24/25

Q3 FY25 net profit more than doubled year-over-year as Sandu shifts to standalone reporting.

Q3 24/25

### Executive summary
- Unaudited standalone financial results for the quarter and nine months ended 31st December 2025 were reviewed and approved by the Board on 6th February 2026.
- Financial statements were prepared in accordance with Indian Accounting Standards (IND AS) and reviewed by statutory auditors.

### Financial highlights
- Revenue from operations for Q3 FY26 was ₹1,876.09 lakhs, up from ₹1,762.11 lakhs in the previous quarter and ₹1,837.29 lakhs in Q3 FY25.
- Net profit for Q3 FY26 stood at ₹97.51 lakhs, compared to ₹52.43 lakhs in the previous quarter and ₹55.55 lakhs in Q3 FY25.
- Total comprehensive income for Q3 FY26 was ₹114.47 lakhs, up from ₹66.31 lakhs in the previous quarter and ₹73.80 lakhs in Q3 FY25.
- Earnings per share (EPS) for Q3 FY26 was ₹1.01, compared to ₹0.54 in the previous quarter and ₹0.57 in Q3 FY25.

### Outlook and guidance
- Management continues to evaluate performance based on revenue and operating income in the Ayurvedic Property Medicines segment.

Sandu Pharmaceuticals (524703) Q3 25/26 earnings summary

Q3 25/26 earnings summary

Executive summary

Financial highlights

Outlook and guidance

Latest events from Sandu Pharmaceuticals